Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 9/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27875627 | 1.00 | USP30 (0.44) | USP30DRD3GAAALDH1A1MEN1 | |
| SCHEMBL4730362 | 0.87 | USP30 (0.55) | USP30DRD3ALDH1A1MEN1KMT2A | |
| SCHEMBL4730357 | 0.87 | USP30 (0.55) | USP30DRD3ALDH1A1MEN1KMT2A | |
| SCHEMBL3375071 | 0.86 | USP30 (0.44) | USP30 | |
| SCHEMBL3372157 | 0.86 | MEN1 (0.49) | USP30MEN1KMT2A | |
| SCHEMBL14150546 | 0.86 | USP30 (0.46) | USP30DRD3MEN1KMT2A | |
| SCHEMBL502854 | 0.86 | USP30 (0.44) | USP30DRD3GAAALDH1A1MEN1 | |
| SCHEMBL3374491 | 0.86 | USP30 (0.44) | USP30 | |
| SCHEMBL3370271 | 0.86 | MEN1 (0.49) | USP30MEN1KMT2A | |
| SCHEMBL3373269 | 0.86 | MEN1 (0.49) | USP30MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266979-A1 | 2-morpholino-4-pyrimidone compounds | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2258701-A1 | 2-morpholino-4-pyrimidone compound | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-1789414-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MAPT, PSEN1, PSEN2 | USP30 4355/4885DRD3 1330/4885GAA 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.